Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Business, Policy & Funding › Regulatory News & FDA Approvals › FDA Approves Genentech's Tecentriq, Cotellic, Zelboraf for BRAF V600-Mutated Melanoma

FDA Approves Genentech's Tecentriq, Cotellic, Zelboraf for BRAF V600-Mutated Melanoma

Jul 31, 2020
|
staff reporter

NEW YORK – The US Food and Drug Administration on Thursday approved the combination of three Genentech drugs, the immune checkpoint inhibitor atezolizumab (Tecentriq), the MEK inhibitor cobimetinib (Cotellic), and the BRAF inhibitor vemurafenib (Zelboraf), for the treatment of BRAF V600-mutated advanced melanoma. 

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

What's Popular?

In Regulatory News & FDA Approvals

  1. Blueprint Medicines to Pursue Ayvakit Approval in Cancer-Causing Mast Cell Disorder

  2. Agios's Tibsovo Trial Fails to Meet Overall Survival Endpoint in IDH1-Mutated Bile Duct Cancer

  3. Blueprint Medicine's Ayvakyt Garners Conditional European Commission Authorization in GIST

  4. EMA Committee Recommends Narrower Lynparza Indication for Metastatic Prostate Cancer Than FDA

  5. FDA Accepts Pfizer's sNDA for Xalkori in Rare ALK-Positive Pediatric Leukemia Indication

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.